Elucid: Funding, Investors & Team (Sep 2026)
Elucid, a medical technology company based in Boston, is using advanced AI technology to provide doctors with a cost-effective way to make better treatment choices for patients with cardiovascular disease. By harnessing the innovative clinical insight offered by Elucid, physicians gain crucial information that allows them to practice precision medicine. Elucid has gained the distinction of being the first FDA-Cleared and CE-marked non-invasive software capable of quantifying atherosclerotic plaque characteristics, such as Lipid Rich Necrotic Core, in comparison to histopathology. The company has also published studies on the derivation of fractional flow reserve (FFRct), which is based on the vasodilative capaUK the vessel wall, as well as the estimation of RNA transcripts (referred to as "Virtual Transcriptomics"). This distinctive data helps doctors make more informed treatment decisions, resulting in improved patient outcomes, better quality of care, and reduced healthcare expenses. The Elucid software is currently available for commercial use in both the United States and Europe.
Elucid has raised $117M across 2 funding rounds on record, the most recent an undisclosed round of $36.5M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Elucid Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Elucid Funding Rounds
Elucid raised $80.0M in a Series C announced in Nov 2023.
1.9 years later, an undisclosed round of $36.5M was announced in Oct 2025.
Elucid Founders and Leadership Team
No contact details are on record for this team yet.
Elucid Funding Compared to Other Biotechnology Startups
Elucid's latest round of $36.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Elucid in Biotechnology and Boston
Companies Similar to Elucid
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Elucid Funding FAQs
What does Elucid do?
Elucid, a medical technology company based in Boston, is using advanced AI technology to provide doctors with a cost-effective way to make better treatment choices for patients with cardiovascular disease. By harnessing the innovative clinical insight offered by Elucid, physicians gain crucial information that allows them to practice precision medicine. Elucid has gained the distinction of being the first FDA-Cleared and CE-marked non-invasive software capable of quantifying atherosclerotic plaque characteristics, such as Lipid Rich Necrotic Core, in comparison to histopathology. The company has also published studies on the derivation of fractional flow reserve (FFRct), which is based on the vasodilative capaUK the vessel wall, as well as the estimation of RNA transcripts (referred to as "Virtual Transcriptomics"). This distinctive data helps doctors make more informed treatment decisions, resulting in improved patient outcomes, better quality of care, and reduced healthcare expenses. The Elucid software is currently available for commercial use in both the United States and Europe.
How much funding has Elucid raised?
Elucid has raised $117M across 2 rounds on record. The most recent is an undisclosed round of $36.5M announced in Oct 2025.
When did Elucid last raise funding?
Elucid's most recent funding round on record is an undisclosed round of $36.5M, announced in Oct 2025.
Who founded Elucid?
FundedIQ lists Andrew J Buckler (Founder) at Elucid.
Where is Elucid headquartered?
Elucid is based in Boston, Massachusetts, United States.
How many employees does Elucid have?
Elucid is in the 51-100 employee band.
How does Elucid's funding compare to other Biotechnology startups?
Elucid's latest round of $36.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Elucid Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Elucid is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.